[go: up one dir, main page]

MX2017015138A - Formulaciones farmaceuticas para liberacion sostenida de ester de sebacoil dinalbufina. - Google Patents

Formulaciones farmaceuticas para liberacion sostenida de ester de sebacoil dinalbufina.

Info

Publication number
MX2017015138A
MX2017015138A MX2017015138A MX2017015138A MX2017015138A MX 2017015138 A MX2017015138 A MX 2017015138A MX 2017015138 A MX2017015138 A MX 2017015138A MX 2017015138 A MX2017015138 A MX 2017015138A MX 2017015138 A MX2017015138 A MX 2017015138A
Authority
MX
Mexico
Prior art keywords
pharmaceutical formulations
ester
dinalbufina
sebacoil
sustained release
Prior art date
Application number
MX2017015138A
Other languages
English (en)
Other versions
MX390384B (es
Inventor
Jung Li Chan-
Chih- Kuang CHOU David
Ding Huang Jin-
Tsai Shin Jr
Wen KUO Shu-
En Tien Yu-
Original Assignee
Lumosa Therapeutics Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lumosa Therapeutics Co Ltd filed Critical Lumosa Therapeutics Co Ltd
Publication of MX2017015138A publication Critical patent/MX2017015138A/es
Publication of MX390384B publication Critical patent/MX390384B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención de relaciona a formulaciones farmacéuticas, de liberación prolongada, inyectables, que comprenden un profármaco de éster de nalbufina homogéneamente disuelto en una solución que comprende un aceite farmacéuticamente aceptable y un solvente de retención miscible en aceite, así como procesos de manufactura y usos médicos de las formulaciones. La invención además proporciona métodos para ajustar la duración de acción de las formulaciones al variar la relación del aceite farmacéuticamente aceptable y el solvente de retención miscible en aceite.
MX2017015138A 2015-05-28 2016-05-27 Formulaciones farmaceuticas para liberacion sostenida de ester de sebacoil dinalbufina. MX390384B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201514723996A 2015-05-28 2015-05-28
US201562255805P 2015-11-16 2015-11-16
PCT/IB2016/000857 WO2016189393A1 (en) 2015-05-28 2016-05-27 Pharmaceutical formulations for sustained release of sebacoyl dinalbuphine ester

Publications (2)

Publication Number Publication Date
MX2017015138A true MX2017015138A (es) 2018-03-28
MX390384B MX390384B (es) 2025-03-11

Family

ID=57392865

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017015138A MX390384B (es) 2015-05-28 2016-05-27 Formulaciones farmaceuticas para liberacion sostenida de ester de sebacoil dinalbufina.

Country Status (15)

Country Link
EP (1) EP3302477B1 (es)
JP (1) JP6935393B2 (es)
KR (1) KR102375798B1 (es)
CN (1) CN106376232B (es)
AU (1) AU2016269337B2 (es)
BR (1) BR112017025395A2 (es)
CA (1) CA2987378C (es)
MX (1) MX390384B (es)
MY (1) MY195509A (es)
NZ (1) NZ738463A (es)
PH (1) PH12017502149A1 (es)
RU (1) RU2718900C2 (es)
TW (1) TWI700087B (es)
WO (1) WO2016189393A1 (es)
ZA (1) ZA201708064B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3094710A1 (en) * 2018-03-29 2019-10-03 Lumosa Therapeutics Co., Ltd. Compositions and methods for treating pruritus
US10807995B2 (en) 2018-07-13 2020-10-20 Alkermes Pharma Ireland Limited Thienothiophene compounds for long-acting injectable compositions and related methods
WO2020012248A1 (en) 2018-07-13 2020-01-16 Alkermes Pharma Ireland Limited Novel naphthylenyl compounds for long-acting injectable compositions and related methods
WO2020094634A1 (en) 2018-11-05 2020-05-14 Alkermes Pharma Ireland Limited Thiophene prodrugs of naltroxene for long-acting injectable compositions and related methods
WO2023020608A1 (zh) * 2021-08-20 2023-02-23 苏州恩华生物医药科技有限公司 一种包含塞纳布啡的药物组合物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69427551T2 (de) * 1993-03-15 2002-05-16 National Science Council, Taipeh/T'ai-Pei Nalbuphinester und diese enthaltende Arzneimittel mit verzögerter Wirkstoffabgabe
US6225321B1 (en) * 1997-06-05 2001-05-01 Oliver Yoa-Pu Hu Long analgesic acting nalbuphine polyester derivative and method of use
DE69917000T2 (de) 1998-02-25 2005-04-21 Abbott Lab Butorphanol enthaltende formulierungen mit verzögerter freisetzung
JP4024992B2 (ja) * 2000-04-27 2007-12-19 オリバー ヤオ−プ フ ポリナルブフィン誘導体及びそれを製造するための方法
US6703398B2 (en) * 2001-11-26 2004-03-09 Oliver Yoa-Pu Hu Orally administered analgesic compositions containing nalbuphine
US20080227805A1 (en) 2007-02-28 2008-09-18 Abbott Laboratories Sustained release parenteral formulations of buprenorphine
CN103142458B (zh) * 2013-01-22 2015-09-09 莱普德制药有限公司 无成瘾性镇痛缓释递药系统的组方与制备方法

Also Published As

Publication number Publication date
EP3302477A4 (en) 2019-01-09
JP6935393B2 (ja) 2021-09-15
CN106376232A (zh) 2017-02-01
AU2016269337A1 (en) 2018-01-18
JP2018522941A (ja) 2018-08-16
PH12017502149A1 (en) 2018-05-28
MY195509A (en) 2023-01-28
KR20180014755A (ko) 2018-02-09
WO2016189393A1 (en) 2016-12-01
MX390384B (es) 2025-03-11
NZ738463A (en) 2023-06-30
AU2016269337B2 (en) 2021-04-08
CA2987378A1 (en) 2016-12-01
BR112017025395A2 (pt) 2018-10-16
TW201705960A (zh) 2017-02-16
RU2017145643A (ru) 2019-06-28
CA2987378C (en) 2023-08-01
TWI700087B (zh) 2020-08-01
ZA201708064B (en) 2023-02-22
RU2718900C2 (ru) 2020-04-15
RU2017145643A3 (es) 2019-10-03
EP3302477A1 (en) 2018-04-11
EP3302477B1 (en) 2024-02-07
KR102375798B1 (ko) 2022-03-17
CN106376232B (zh) 2021-06-11

Similar Documents

Publication Publication Date Title
CO2018002063A2 (es) Análogos novedosos de nucleósidos sustituidos en el anillo aromático bicíclico 6-6 para su uso como inhibidores de prmt5
CL2020000747A1 (es) Formulaciones de niraparib.
GT201400178A (es) Compuestos de oxazolidin-2-ona y usos de los mismos como inhibidores de la pi3ks
MX2017004906A (es) Dihidropirrolopiridinas inhibidoras del receptor huerfano-gamma.
CL2016000408A1 (es) Composiciones farmaceuticas que contienen diastereomeros macrolidos, metodos para su sintesis y usos terapeuticos.
CO2017013708A2 (es) Macrociclos peptídicos contra acinetobacter baumannii.
CR20160518A (es) Compuestos para tratar atrofia muscular espinal
MX2018015709A (es) Derivados de azabencimidazol como inhibidores de pi3k beta.
UY35146A (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
DOP2017000278A (es) Piridinas sustituidas y método de uso
MX2018000280A (es) Oxiesteroles y metodos de uso de los mismos.
CL2017000820A1 (es) Compuestos de aminopurina sustituida, composiciones de los mismos, y metodos de tratamiento con los mismos
ES2552754T1 (es) Formulaciones de daptomicina y usos de la misma
MX2017015138A (es) Formulaciones farmaceuticas para liberacion sostenida de ester de sebacoil dinalbufina.
CU20170153A7 (es) Compuestos tricíclicos útiles como inhibidores de la fosfodiesterasa
MX2014005342A (es) Inhibidores del virus de la hepatitis c.
MX2016014854A (es) Compuestos y composiciones para inducir condrogenesis.
MX2019006291A (es) Composiciones de lactato de calcio y metodos de uso.
CR20150248A (es) Derivados de oxazolidin-2-ona-pirimidina
MX2018004304A (es) DERIVADOS DE QUINOXALINA Y PIRIDOPRAZINA COMO INHIBIDORES DE PI3Kß.
ECSP13013012A (es) Análogos del ácido epoxieicosatrienoicos y métodos de preparación
CO2017006958A2 (es) Formulaciones farmacéuticas que comprenden cangrelor de alta pureza y métodos para la preparación y uso de los mismos
BR112017009289A2 (pt) métodos de administrar composições de amantadina
UY36228A (es) Derivados de heteroarilo como inhibidores de aldosterona sintasa (cyp11b2) y composiciones farmacéuticas que los contienen
MX2017013137A (es) Derivados de cromeno como inhibidores de las fosfoinositido-3-cina sas.